Echocardiography Laboratory, Barts Heart Centre, St Bartholomew's Hospital, London, UK; Electrophysiology Department, Barts Heart Centre, St. Bartholomew's Hospital, London, UK; Institute of Cardiovascular Science, UCL, London, UK.
University College London Hospitals NHS Trust, London, UK.
Int J Cardiol. 2020 Nov 15;319:52-56. doi: 10.1016/j.ijcard.2020.05.062. Epub 2020 May 27.
The long-term effect of tricuspid regurgitation (TR) after device implantation on long-term mortality remains unknown. In the present study, we sought to examine whether patients undergoing an implantable cardiac device procedure (pacemaker, cardiac defibrillator or cardiac resynchronisation therapy) have an increased risk of TR and to determine the effect of this on long-term survival.
A total of 304 patients who underwent device implant and had pre- and post-implant transthoracic echocardiogram were included in the analysis. All-cause mortality was the study endpoint over a follow-up period of median 11.6 years.
New ≥ moderate tricuspid regurgitation post-device implantation developed in 66/304 (21.7%) patients. New right ventricular dysfunction post-device implantation occurred in 59/304 (19.4%) patients. Independent predictors of new RV dysfunction were ischaemic heart disease (OR 4.23, 95% CI 1.58 - 11.33, p = 0.004), left ventricular impairment (OR 2.74, 95% CI 5.41 - 30.00, p < 0.0001) and new ≥ moderate TR (OR 7.72, 95% CI 3.27 - 18.23, p < 0.001). Independent predictors of mortality were new ≥ moderate TR [HR: 3.14 (95% CI 1.29 - 7.63) p = 0.01] and new RV impairment [HR: 2.82 (95% CI 1.33 - 5.98) p = 0.01.
Worsening TR and RV dysfunction post-device implantation is common. New post-implant ≥ moderate TR is associated with increased risk of new RV impairment and poor long term (>10 years) survival.
器械植入后三尖瓣反流(TR)对长期死亡率的长期影响尚不清楚。本研究旨在探讨植入式心脏器械(起搏器、心脏除颤器或心脏再同步治疗)患者是否有发生 TR 的风险增加,并确定其对长期生存的影响。
共纳入 304 例接受器械植入并接受植入前和植入后经胸超声心动图检查的患者。全因死亡率是中位随访 11.6 年后的研究终点。
66/304(21.7%)患者在器械植入后出现新的≥中度 TR。59/304(19.4%)患者在器械植入后出现新的右心室功能障碍。新的右心室功能障碍的独立预测因素为缺血性心脏病(OR 4.23,95%CI 1.58-11.33,p=0.004)、左心室损害(OR 2.74,95%CI 5.41-30.00,p<0.0001)和新的≥中度 TR(OR 7.72,95%CI 3.27-18.23,p<0.001)。死亡率的独立预测因素为新的≥中度 TR[HR:3.14(95%CI 1.29-7.63),p=0.01]和新的右心室损害[HR:2.82(95%CI 1.33-5.98),p=0.01]。
器械植入后 TR 恶化和右心室功能障碍很常见。新植入后≥中度 TR 与新发右心室损害和较差的长期(>10 年)生存率相关。